Novartis' Sandoz to acquire antifungal drug Mycamine from Astellas

Jan. 24, 2023 4:29 AM ETAstellas Pharma Inc. (ALPMY), ALPMF, NVSBy: Ravikash, SA News Editor2 Comments

Novartis logo on the office building in San Diego, CA, USA.

JHVEPhoto/iStock Editorial via Getty Images

  • Novartis' (NYSE:NVS) Sandoz is acquiring worldwide product rights to Astellas Pharma's (OTCPK:ALPMY) (OTCPK:ALPMF) antifungal drug Mycamine.
  • Mycamine belongs to a class of antifungal drugs called echinocandin. The drug is used as a preventive therapy in hematology and oncology patients, and widely

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.